The agreement with one of the top five veterinary pharma companies to collaborate on the development of CryoShot Canine is recognition of the good progress that Regeneus has made developing its regenerative medicine products and cancer vaccines. At its recent AGM, Regeneus confirmed that it anticipates winning the much bigger prize of a manufacturing and development partner in Japan for its Progenza off-the-shelf human stem cell product by Q116. We maintain our valuation of A$106m (A$0.51/share) ahead of this potential re-rating catalyst.
